NOK 1.9
(-5.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -48.58 Million NOK | -29.95% |
2022 | -37.38 Million NOK | -192.14% |
2021 | 40.57 Million NOK | 287.21% |
2020 | -21.67 Million NOK | -602.93% |
2019 | -3.08 Million NOK | -168.19% |
2018 | -1.14 Million NOK | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -12.09 Million NOK | 0.0% |
2024 Q1 | -12.09 Million NOK | 6.99% |
2023 Q4 | -13 Million NOK | 0.0% |
2023 FY | -48.58 Million NOK | -29.95% |
2023 Q1 | 1.2 Million NOK | 111.34% |
2023 Q3 | -13 Million NOK | 0.0% |
2023 Q2 | - NOK | -100.0% |
2022 Q4 | -10.58 Million NOK | 0.0% |
2022 FY | -37.38 Million NOK | -192.14% |
2021 FY | 40.57 Million NOK | 287.21% |
2020 FY | -21.67 Million NOK | -602.93% |
2019 FY | -3.08 Million NOK | -168.19% |
2018 FY | -1.14 Million NOK | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Aqua Bio Technology ASA | -17.85 Million NOK | -172.082% |
ArcticZymes Technologies ASA | 15.74 Million NOK | 408.562% |
BerGenBio ASA | -191.81 Million NOK | 74.671% |
Hofseth BioCare ASA | -102.52 Million NOK | 52.612% |
PCI Biotech Holding ASA | -22.24 Million NOK | -118.453% |
Thor Medical ASA | -7.16 Million NOK | -578.578% |
Ultimovacs ASA | -215.73 Million NOK | 77.479% |